Logo image of SNTI

SENTI BIOSCIENCES INC (SNTI) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SNTI - US81726A2096 - Common Stock

1.04 USD
-0.01 (-0.95%)
Last: 12/31/2025, 8:00:02 PM
1.05 USD
+0.01 (+0.96%)
After Hours: 12/31/2025, 8:00:02 PM
Fundamental Rating

2

Taking everything into account, SNTI scores 2 out of 10 in our fundamental rating. SNTI was compared to 530 industry peers in the Biotechnology industry. While SNTI seems to be doing ok healthwise, there are quite some concerns on its profitability. SNTI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SNTI has reported negative net income.
In the past year SNTI has reported a negative cash flow from operations.
SNTI had negative earnings in each of the past 5 years.
In the past 5 years SNTI always reported negative operating cash flow.
SNTI Yearly Net Income VS EBIT VS OCF VS FCFSNTI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -90.31%, SNTI is doing worse than 72.45% of the companies in the same industry.
SNTI's Return On Equity of -585.90% is on the low side compared to the rest of the industry. SNTI is outperformed by 75.66% of its industry peers.
Industry RankSector Rank
ROA -90.31%
ROE -585.9%
ROIC N/A
ROA(3y)-48.54%
ROA(5y)-48.78%
ROE(3y)-85.31%
ROE(5y)-82.35%
ROIC(3y)N/A
ROIC(5y)N/A
SNTI Yearly ROA, ROE, ROICSNTI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

SNTI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNTI Yearly Profit, Operating, Gross MarginsSNTI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

4

2. Health

2.1 Basic Checks

SNTI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNTI has been increased compared to 1 year ago.
SNTI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SNTI has a worse debt to assets ratio.
SNTI Yearly Shares OutstandingSNTI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
SNTI Yearly Total Debt VS Total AssetsSNTI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -12.79, we must say that SNTI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SNTI (-12.79) is worse than 75.85% of its industry peers.
SNTI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.79
ROIC/WACCN/A
WACC8.77%
SNTI Yearly LT Debt VS Equity VS FCFSNTI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

SNTI has a Current Ratio of 1.51. This is a normal value and indicates that SNTI is financially healthy and should not expect problems in meeting its short term obligations.
SNTI has a Current ratio of 1.51. This is amonst the worse of the industry: SNTI underperforms 80.94% of its industry peers.
A Quick Ratio of 1.51 indicates that SNTI should not have too much problems paying its short term obligations.
SNTI has a Quick ratio of 1.51. This is amonst the worse of the industry: SNTI underperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.51
SNTI Yearly Current Assets VS Current LiabilitesSNTI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.10% over the past year.
SNTI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)82.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SNTI will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.52% on average per year.
Based on estimates for the next years, SNTI will show a very strong growth in Revenue. The Revenue will grow by 73.65% on average per year.
EPS Next Y81.81%
EPS Next 2Y37.96%
EPS Next 3Y23.63%
EPS Next 5Y13.52%
Revenue Next Year-76.19%
Revenue Next 2Y-22.85%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.65%

3.3 Evolution

SNTI Yearly Revenue VS EstimatesSNTI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 2031 2032 100M 200M 300M 400M
SNTI Yearly EPS VS EstimatesSNTI Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10 -15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNTI. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNTI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNTI Price Earnings VS Forward Price EarningsSNTI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNTI Per share dataSNTI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as SNTI's earnings are expected to grow with 23.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.96%
EPS Next 3Y23.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNTI!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SENTI BIOSCIENCES INC

NASDAQ:SNTI (12/31/2025, 8:00:02 PM)

After market: 1.05 +0.01 (+0.96%)

1.04

-0.01 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners22.3%
Inst Owner Change-12.99%
Ins Owners0.85%
Ins Owner Change0%
Market Cap27.34M
Revenue(TTM)N/A
Net Income(TTM)-47.58M
Analysts84
Price Target11.73 (1027.88%)
Short Float %14.63%
Short Ratio0.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.81%
Min EPS beat(2)-19.38%
Max EPS beat(2)39%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.54%
PT rev (3m)-14.81%
EPS NQ rev (1m)5.17%
EPS NQ rev (3m)5.17%
EPS NY rev (1m)-5.94%
EPS NY rev (3m)-11.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-33.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.37
P/tB 3.37
EV/EBITDA N/A
EPS(TTM)-2.79
EYN/A
EPS(NY)-1.44
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.9
OCFYN/A
SpS0
BVpS0.31
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -90.31%
ROE -585.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.54%
ROA(5y)-48.78%
ROE(3y)-85.31%
ROE(5y)-82.35%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.62%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.51
Altman-Z -12.79
F-Score4
WACC8.77%
ROIC/WACCN/A
Cap/Depr(3y)1099.41%
Cap/Depr(5y)844.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.06%
EPS Next Y81.81%
EPS Next 2Y37.96%
EPS Next 3Y23.63%
EPS Next 5Y13.52%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-76.19%
Revenue Next 2Y-22.85%
Revenue Next 3Y-25.99%
Revenue Next 5Y73.65%
EBIT growth 1Y-5.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7.89%
OCF growth 3YN/A
OCF growth 5YN/A

SENTI BIOSCIENCES INC / SNTI FAQ

What is the ChartMill fundamental rating of SENTI BIOSCIENCES INC (SNTI) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SNTI.


What is the valuation status for SNTI stock?

ChartMill assigns a valuation rating of 1 / 10 to SENTI BIOSCIENCES INC (SNTI). This can be considered as Overvalued.


Can you provide the profitability details for SENTI BIOSCIENCES INC?

SENTI BIOSCIENCES INC (SNTI) has a profitability rating of 0 / 10.


How financially healthy is SENTI BIOSCIENCES INC?

The financial health rating of SENTI BIOSCIENCES INC (SNTI) is 4 / 10.